Slide 1: Natural Human Antibodies to Treat Human Diseases
For personal use only ASX: PAB Natural Human Antibodies to Treat Human Diseases Shareholder Teleconference and Webcast 1 July 2009 Dan Devine Chief Executive Officer
Slide 2: Agenda
For personal use only Agenda Patrys Overview Strategic Objectives - Update $6.8 Million Rights Issue Timeline Upcoming Milestones Question & Answer Period 2
Slide 3: Company Overview
For personal use only Company Overview Strong competitive position in exploding antibody market First to systematically advance anti-cancer natural human antibodies into human trials Long-term patent protection in increasingly competitive market Diverse and multiple commercial opportunities Combinat
Slide 4: Strategic Objectives
For personal use only Strategic Objectives 1. Maintain strong financial position 2. Advance leads to human trials 3. Partner early stage products to maximise commercial opportunities 4. Reduce development costs and risks by acquiring mature products at favourable prices 5. Expand pipeline and intell
Slide 5: Maintain Strong Financial Position
For personal use only Maintain Strong Financial Position July 2007 IPO: support company until Oct 2009 $6.8 million renounceable rights issue 25 cents/share; technology value similar to July 2007 IPO $5,000,000 underwritten by PNK Holdings Expected to close on 12 August 2009 Projected cash position
Slide 6: PAT-SM6 and PAT-LM1 Development - I
For personal use only PAT-SM6 and PAT-LM1 Development - I Development Goals Develop manufacturing system to support advanced development Complete preclinical safety studies Commence and conclude human clinical trials Challenges First to produce/develop anti-cancer natural human antibodies Closing of
Slide 7: PAT-SM6 and PAT-LM1 Development - II
For personal use only PAT-SM6 and PAT-LM1 Development - II PAT-SM6 Product material produced for human trial; under final quality testing Target start of human trial in 3QCY2009; data in 1HCY2010 PAT-LM1 Start of human clinical trial after start of PAT-SM6 trial Sharp focus on PAT-SM6 clinical plan;
Slide 8: Partnering Early Stage Products
For personal use only Partnering Early Stage Products Deep pipeline permits internal development and partnering In advanced negotiations with international company re: multiple early stage products Multiple & diverse opportunities for commercial success Share development costs & risks with larger pa
Slide 9: Product Acquisition Opportunities
For personal use only Product Acquisition Opportunities US/European companies with promising later stage human antibodies; no capital markets/financing needed to advance Large biotech/pharma companies busy merging Acquisition opportunities with favourable pricing; back-ended milestone and royalty pa
Slide 10: Pipeline Expansion – Internal R&D
For personal use only Pipeline Expansion – Internal R&D Advancement of current lead products Generate new lead products and new disease targets Cost effective and under complete internal control Uniquely broad and valuable intellectual property portfolio: 17 total patent families 7 new patent famili
Slide 11: $6.8 Million Rights Issue Timeline
For personal use only $6.8 Million Rights Issue Timeline Announcement of Rights Issue/Share Top Up Offer 29 June 2009 Dispatch notice of meeting to shareholders 30 June 2009 "Ex" Date (date securities are quoted on an ex basis) 1 July 2009 Record Date 7 July 2009 Dispatch of Rights Issue /Share Top
Slide 12: Upcoming Milestones
For personal use only Upcoming Milestones Strategic Objective Milestones Financing August 2009: close rights issue 3QCY2009: apply for approval to commence human trial PAT-SM6 Development 1HCY2010: human clinical trial data 2QCY2010: partnering discussions 2HCY2009: advance partnering discussions PA
Slide 13: Summary
For personal use only Summary Strong competitive position Diverse and multiple commercial opportunities Proven ability to adjust to market/operational challenges Short-term value driving milestones 13
Slide 14: Questions and Answers
For personal use only Questions and Answers 14